Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Third Phase II study of eFT508

Trial Profile

Third Phase II study of eFT508

Planning
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Tomivosertib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2018 New trial record
    • 16 Apr 2018 According to an Effector Therapeutics media release, this study is expected to be initiated by the end of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top